176 related articles for article (PubMed ID: 2693029)
41. Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia.
Ebert R; Creutzfeldt W
Acta Diabetol Lat; 1989; 26(1):1-15. PubMed ID: 2665406
[TBL] [Abstract][Full Text] [Related]
42. Alteration of postprandial glucose and insulin concentrations with meal frequency and composition.
Kanaley JA; Heden TD; Liu Y; Fairchild TJ
Br J Nutr; 2014 Nov; 112(9):1484-93. PubMed ID: 25231499
[TBL] [Abstract][Full Text] [Related]
43. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state.
Amland PF; Jorde R; Aanderud S; Burhol PG; Giercksky KE
Scand J Gastroenterol; 1985 Apr; 20(3):315-20. PubMed ID: 3890139
[TBL] [Abstract][Full Text] [Related]
44. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.
Thondam SK; Daousi C; Wilding JP; Holst JJ; Ameen GI; Yang C; Whitmore C; Mora S; Cuthbertson DJ
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E224-E233. PubMed ID: 28073779
[TBL] [Abstract][Full Text] [Related]
45. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
Irwin N; Gault VA; Green BD; Greer B; McCluskey JT; Harriott P; O'Harte FP; Flatt PR
Biol Chem; 2004 Sep; 385(9):845-52. PubMed ID: 15493880
[TBL] [Abstract][Full Text] [Related]
46. Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.
Verdonk CA; Rizza RA; Nelson RL; Go VL; Gerich JE; Service FJ
J Clin Invest; 1980 May; 65(5):1119-25. PubMed ID: 6988457
[TBL] [Abstract][Full Text] [Related]
47. Gastric inhibitory polypeptide in newly diagnosed ketotic type I (insulin-dependent) diabetics.
Krarup T; Madsbad S; Moody AJ
Acta Med Scand; 1988; 223(5):437-41. PubMed ID: 3287838
[TBL] [Abstract][Full Text] [Related]
48. GIP contributes to islet trihormonal abnormalities in type 2 diabetes.
Chia CW; Odetunde JO; Kim W; Carlson OD; Ferrucci L; Egan JM
J Clin Endocrinol Metab; 2014 Jul; 99(7):2477-85. PubMed ID: 24712564
[TBL] [Abstract][Full Text] [Related]
49. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells.
Almind K; Ambye L; Urhammer SA; Hansen T; Echwald SM; Holst JJ; Gromada J; Thorens B; Pedersen O
Diabetologia; 1998 Oct; 41(10):1194-8. PubMed ID: 9794107
[TBL] [Abstract][Full Text] [Related]
50. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
51. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
52. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
53. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
[TBL] [Abstract][Full Text] [Related]
54. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
[TBL] [Abstract][Full Text] [Related]
55. Gastric inhibitory polypeptide (GIP): a therapeutic possibility?
Moody AJ; Jones IR; Krarup T; Owens DR; Saurbrey N
Acta Paediatr Scand Suppl; 1985; 320():66-71. PubMed ID: 3914816
[No Abstract] [Full Text] [Related]
56. Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.
Meier JJ; Nauck MA; Kask B; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
World J Gastroenterol; 2006 Mar; 12(12):1874-80. PubMed ID: 16609993
[TBL] [Abstract][Full Text] [Related]
57. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
58. Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates.
Higgins PB; Shade RE; Rodríguez-Sánchez IP; Garcia-Forey M; Tejero ME; Voruganti VS; Cole SA; Comuzzie AG; Folli F
Am J Physiol Endocrinol Metab; 2016 Oct; 311(4):E661-E670. PubMed ID: 27530231
[TBL] [Abstract][Full Text] [Related]
59. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
60. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
